Literature DB >> 2198026

Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

J M Aerts1, W E Donker-Koopman, S Brul, S Van Weely, M C Sa Miranda, J A Barranger, J M Tager, A W Schram.   

Abstract

In Gaucher disease (glucosylceramide lipidosis), deficiency of glucocerebrosidase causes pathological storage of glucosylceramide, particularly in the spleen. A comparative biochemical and immunological analysis has therefore been made of glucocerebrosidase in spleens from normal subjects (n = 4) and from Gaucher disease patients with non-neuronopathic (n = 5) and neuronopathic (n = 5) phenotypes. The spleens from all Gaucher disease patients showed markedly decreased glucocerebrosidase activity. Discrimination of different phenotypes of Gaucher disease was not possible on the basis of the level of residual enzyme activity, or by measurements, using the immunopurified enzyme, of kinetic constants, pI or molecular mass forms. A severe decrease was found in the specific activity of glucocerebrosidase purified to homogeneity from the spleen of a patient with the non-neuronopathic phenotype of Gaucher disease, as compared with that of the enzyme purified from the spleen of a normal subject. This finding was confirmed by an immunological method developed for accurate assessment of the relative enzyme activity per molecule of glucocerebrosidase protein. The method revealed that the residual enzyme in the spleens of all investigated patients with a non-neuronopathic course of Gaucher disease had a more than 7-fold decreased activity of glucocerebrosidase (measured in the presence of taurocholate) per molecule of enzyme, and that the concentration of glucocerebrosidase molecules in the spleens of these patients was near normal. Observations made with immunoblotting experiments were consistent with these findings. In contrast, in the spleens of patients with neuronopathic phenotypes of Gaucher disease, the concentration of glucocerebrosidase molecules was severely decreased.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198026      PMCID: PMC1131536          DOI: 10.1042/bj2690093

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Systematic purification of five glycosidases from Streptococcus (Diplococcus) pneumoniae.

Authors:  L R Glasgow; J C Paulson; R L Hill
Journal:  J Biol Chem       Date:  1977-12-10       Impact factor: 5.157

2.  Isolation of heat-stable glucocerebrosidase activators from the spleens of three variants of Gaucher's disease.

Authors:  S P Peters; C J Coffee; R H Glew; R E Lee; D A Wenger; S C Li; Y T Li
Journal:  Arch Biochem Biophys       Date:  1977-09       Impact factor: 4.013

3.  Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia.

Authors:  R H Aster
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

4.  Monoclonal antibodies against human beta-glucocerebrosidase.

Authors:  R A Barneveld; F P Tegelaers; E I Ginns; P Visser; E A Laanen; R O Brady; H Galjaard; J A Barranger; A J Reuser; J M Tager
Journal:  Eur J Biochem       Date:  1983-08-15

5.  Protein activator (coglucosidase) for the hydrolysis of beta-glucosides.

Authors:  N S Radin; S L Berent
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

6.  Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.

Authors:  P G Pentchev; B Neumeyer; L Svennerholm; C G Groth; R O Brady
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

7.  Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.

Authors:  E I Ginns; R O Brady; S Pirruccello; C Moore; S Sorrell; F S Furbish; G J Murray; J Tager; J A Barranger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  Determination of Gaucher's disease phenotypes with monoclonal antibody.

Authors:  E I Ginns; F P Tegelaers; R Barneveld; H Galjaard; A J Reuser; R O Brady; J M Tager; J A Barranger
Journal:  Clin Chim Acta       Date:  1983-07-15       Impact factor: 3.786

9.  Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.

Authors:  J E Bergmann; G A Grabowski
Journal:  Am J Hum Genet       Date:  1989-05       Impact factor: 11.025

10.  Radioimmunoassay of platelet factor 4 and beta-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation.

Authors:  K L Kaplan; H L Nossel; M Drillings; G Lesznik
Journal:  Br J Haematol       Date:  1978-05       Impact factor: 6.998

View more
  4 in total

Review 1.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

2.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  Greater risk of parkinsonism associated with non-N370S GBA1 mutations.

Authors:  M J Barrett; P Giraldo; J L Capablo; P Alfonso; P Irun; B Garcia-Rodriguez; M Pocovi; G M Pastores
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

Review 4.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.